The IMPACT EU consortium gathered in Milan on 9–10 October 2025 for its 2nd Year Meeting, hosted by Consorzio Italbiotec. 

Partners shared results, reviewed progress, and aligned on upcoming activities focused on arrhythmogenic cardiomyopathy (ACM). Bárbara Gomes presented AccelBio and our role in supporting biomedical innovation, while Mariana de Araújo Branco showcased how the organoids under development will contribute to identifying new therapeutic targets and therapies for ACM. 

We are proud to be part of this journey toward more precise and effective therapies for cardiovascular disease.